bluebird bio Announces Data Demonstrating First Four Patients with β-Thalassemia Major Treated with LentiGlobin™ are Transfusion-Free Read more about bluebird bio Announces Data Demonstrating First Four Patients with β-Thalassemia Major Treated with LentiGlobin™ are Transfusion-Free
bluebird bio Reports Fiscal Third Quarter 2014 Financial Results Read more about bluebird bio Reports Fiscal Third Quarter 2014 Financial Results
James M. DeTore joins bluebird bio as Chief Financial Officer Read more about James M. DeTore joins bluebird bio as Chief Financial Officer
bluebird bio to Present at Three Upcoming Health Care Conferences Read more about bluebird bio to Present at Three Upcoming Health Care Conferences
bluebird bio to Present LentiGlobin Clinical Data at the American Society of Hematology Conference Read more about bluebird bio to Present LentiGlobin Clinical Data at the American Society of Hematology Conference
bluebird bio Announces First Patient with Sickle Cell Disease Transplanted with LentiGlobin Gene Therapy Read more about bluebird bio Announces First Patient with Sickle Cell Disease Transplanted with LentiGlobin Gene Therapy
bluebird bio to Present at Morgan Stanley Global Health Care Conference Read more about bluebird bio to Present at Morgan Stanley Global Health Care Conference
bluebird bio Reports Fiscal Second Quarter 2014 Financial Results Read more about bluebird bio Reports Fiscal Second Quarter 2014 Financial Results
bluebird bio to Present at Two Upcoming Health Care Conferences Read more about bluebird bio to Present at Two Upcoming Health Care Conferences
bluebird bio Appoints Mark Vachon to its Board of Directors Read more about bluebird bio Appoints Mark Vachon to its Board of Directors